PT  - JOURNAL ARTICLE
AU  - Courraud, Jeremie
AU  - Chater-Diehl, Eric
AU  - Durand, Benjamin
AU  - Vincent, Marie
AU  - del Mar Muniz Moreno, Maria
AU  - Boujelbene, Imène
AU  - Drouot, Nathalie
AU  - Genschik, Loréline
AU  - Schaefer, Elise
AU  - Nizon, Mathilde
AU  - Gerard, Bénédicte
AU  - Abramowicz, Marc
AU  - Cogné, Benjamin
AU  - Bronicki, Lucas
AU  - Burglen, Lydie
AU  - Barth, Magalie
AU  - Charles, Perrine
AU  - Colin, Estelle
AU  - Coubes, Christine
AU  - David, Albert
AU  - Delobel, Bruno
AU  - Demurger, Florence
AU  - Passemard, Sandrine
AU  - Denommé, Anne-Sophie
AU  - Faivre, Laurence
AU  - Feger, Claire
AU  - Fradin, Mélanie
AU  - Francannet, Christine
AU  - Genevieve, David
AU  - Goldenberg, Alice
AU  - Guerrot, Anne-Marie
AU  - Isidor, Bertrand
AU  - Johannesen, Katrine M.
AU  - Keren, Boris
AU  - Kibæk, Maria
AU  - Kuentz, Paul
AU  - Mathieu-Dramard, Michele
AU  - Demeer, Bénédicte
AU  - Metreau, Julia
AU  - Møller, Rikke Steensbjerre
AU  - Moutton, Sébastien
AU  - Pasquier, Laurent
AU  - Pilekær Sørensen, Kristina
AU  - Perrin, Laurence
AU  - Renaud, Mathilde
AU  - Saugier, Pascale
AU  - Svane, Joane
AU  - Thevenon, Julien
AU  - Them, Frederic Tran Mau
AU  - Tronhjem, Cathrine Elisabeth
AU  - Vitobello, Antonio
AU  - Layet, Valerie
AU  - Birling, Marie-Christine
AU  - Drunat, Severine
AU  - Bayat, Allan
AU  - Dubourg, Christèle
AU  - Chehadeh, Salima El
AU  - Fagerberg, Christina
AU  - Mignot, Cyril
AU  - Guipponi, Michel
AU  - Bienvenu, Thierry
AU  - Herault, Yann
AU  - Thompson, Julie
AU  - Willems, Marjolaine
AU  - Mandel, Jean-Louis
AU  - Weksberg, Rosanna
AU  - Piton, Amélie
TI  - Integrative approach to interpret DYRK1A variants, leading to a frequent neurodevelopmental disorder
AID  - 10.1101/2021.01.20.21250155
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.20.21250155
4099  - http://medrxiv.org/content/early/2021/01/26/2021.01.20.21250155.short
4100  - http://medrxiv.org/content/early/2021/01/26/2021.01.20.21250155.full
AB  - DYRK1A-related intellectual disability (ID) is among the most frequent monogenic form of ID. We refined the description of this disorder by reporting clinical and molecular data of forty individuals with ID harboring DYRK1A variants. We developed a combination of tools to interpret missense variants, which remains a major challenge in human genetics: i) a specific DYRK1A clinical score, ii) amino acid conservation data generated from one hundred of DYRK1A sequences across different taxa, iii) in vitro overexpression assays to study level, cellular localization, and kinase activity of DYRK1A mutant proteins, and iv) a specific blood DNA methylation signature. This integrative approach was successful to reclassify several variants as pathogenic. However, we questioned the involvement of some others, such as p.Thr588Asn, yet reported as pathogenic, and showed it does not cause obvious phenotype in mice, emphasizing the need to take care when interpreting variants, even those occurring de novo.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors also thank the Agence de Biomedecine and Fondation APLM for their financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Affected individuals were referred by clinical genetic services and a genetic testing was done as part of routine clinical care. All patients enrolled and/or their legal representative have signed informed consent for research use and authorization for publication. All the institutions received local IRB approval to use these data in research purpose. The main IRB approval was obtained from the Ethics Committee of the Strasbourg University Hospital (CCPPRB).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe variants have been sumbitted to clinvar. All data are available upon request